Catapult Sports Ltd

CAT

Catapult Group International Ltd. engages in the development and supply of wearable athlete tracking and analytics solutions. The company is headquartered in Richmond, Victoria. The company went IPO on 2014-12-19. Its products are designed to optimize performance, avoid injury, and improve return to play. Its three main product verticals are: Performance & Health, Tactics & Coaching, and Media & Other. The Performance & Health is engaged in the design, development and supply of wearable technology and athlete monitoring software solutions to sports teams, athletes, and the prosumer market. Tactics & Coaching is engaged in the design, development and supply of video analysis, editing, and publishing software solutions to sports teams. Media & Other provides media licensing, athlete management and professional services to customers. The firm's solutions consist of athlete monitoring, video analysis, racing analysis, recruiting, and content licensing.

De.Mem Limited

DEM

De.mem Ltd. operates as a holding company. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2017-04-07. The firm provides systems to municipalities, residential developments, and hotels/resorts across the Asia Pacific region. The company offers solutions for equipment, services, chemicals and consumables to its clients, for the ongoing operations of their water and wastewater treatment plants. Its segments include Membrane systems, Specialty chemicals, Pumps, Services and Equipment, and Services (Long term Build, Own, Operate (BOO) and Operations and Maintenance (O&M) contracts). The company is also engaged in the sale of specialty chemicals, small equipment and consumables, domestic water treatment systems, and replacement of membrane cartridges. The company commercializes an array of proprietary hollow-fiber membrane technologies.

ResMed Inc.

RMD

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. The company is headquartered in San Diego, California and currently employs 10,600 full-time employees. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. The company also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.

Superloop Limited

SLC

Superloop Ltd. engages in the provision of connectivity services in the Asia Pacific region. The company is headquartered in Sydney, New South Wales. The company went IPO on 2015-06-04. The firm operates through three segments: Wholesale, Business and Consumer. The Wholesale segment is defined by large scale telecommunications, data and technology customers who purchase various connectivity services to support their core business services, as well as retail Internet service providers who do not have access to a connectivity network of their own. The Business segment is defined by small, medium and large corporate customers who purchase connectivity services to facilitate their core business. The Consumer segment is defined by customers who purchase basic Internet and mobile phone products for domestic residential use. Its products include national broadband network (NBN) access, NBN TC2, NBN Enterprise Ethernet, dark fiber, fixed wireless access, third party access, security, managed Wi-Fi, international ethernet, wavelength and international (including Indigo) subsea cable capacity.

Bcal Diagnostics Limited

BDX

BCAL Diagnostics Ltd. develops screening tests for the early detection of breast cancer. The company is headquartered in Sydney, New South Wales. The company went IPO on 2021-07-21. The Company’s core activity is the development of a novel blood screening test to improve the early diagnosis and monitoring of breast cancer, which is available to all women. Its non-invasive blood test, BREASTEST plus, is the product in the Company’s BREASTEST range of non-invasive, lipid-based breast cancer diagnostics. BREASTEST plus is a class blood test that measures a panel of lipids, using Liquid Chromatography Mass Spectrometry, to identify a lipidomic breast cancer signature. BREASTEST plus is a rule-out test that has been designed to be used in women with dense breasts and alongside mammography to improve screening and diagnostic outcomes for women.